HEALTH ACT 1947 (SECTIONS 31AB AND 31AD) (COVID-19) (OPERATION OF CERTAIN INDOOR PREMISES) (AMENDMENT) (NO. 8) REGULATIONS 2021
HEALTH ACT 1947 (SECTIONS 31AB AND 31AD) (COVID-19)  
(OPERATION OF CERTAIN INDOOR PREMISES) (AMENDMENT)  
(NO. 8) REGULATIONS 2021

I, STEPHEN DONNELLY, Minister for Health, in exercise of the powers conferred on me by sections 5 and 31AB and 31AD (inserted by section 3 of the Health (Amendment) (No. 2) Act 2021 (No. 24 of 2021)) of the Health Act 1947 (No. 28 of 1947) and —

(a) having regard to the matters specified in subsection (2) of section 31A, and

(b) having consulted with the Minister for Foreign Affairs, the Minister for Housing, Local Government and Heritage, the Minister for Transport, the Minister for Enterprise, Trade and Employment, the Minister for Finance, the Minister for Justice and the Minister for Tourism, Culture, Arts, Gaeltacht, Sport and Media,

hereby make the following regulations:

1. (1) These Regulations may be cited as the Health Act 1947 (Sections 31AB and 31AD) (Covid-19) (Operation of certain indoor premises) (Amendment) (No.8) Regulations 2021.

(2) These Regulations shall come into operation on the 10th day of November 2021.

2. The Health Act 1947 (Sections 31AB and 31AD) (Covid-19) (Operation of certain indoor premises) Regulations (S.I. No. 385 of 2021) are amended —

(a) in Regulation 1(2), by the substitution of “9th day of January 2022” for “9th day of November 2021”, and

(b) in Regulation 5(3), by the substitution of the following definition for the definition of “vaccinated person”:

“vaccinated person’ means –

(a) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘Spikevax (previously COVID-19 Vaccine Moderna) CX-024414’ has been administered, that person not less than 14 days after the second dose of the medicinal product concerned has been administered to him or her,
(b) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘Vaxzevria (previously COVID-19 Vaccine AstraZeneca) ChAdOx1-SARS-COV-2’, also known as ‘Covishield’, has been administered, that person not less than 15 days after the second dose of the medicinal product concerned has been administered to him or her,

(c) in relation to a person to whom the medicinal product authorised for active immunisation to prevent Covid-19 known as ‘Comirnaty BNT162b2’ has been administered, that person not less than 7 days after the second dose of the medicinal product concerned has been administered to him or her,

(d) in relation to a person to whom the medicinal product authorised for active immunisation to prevent Covid-19 known as ‘COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant])’ has been administered, that person not less than 14 days after the medicinal product concerned has been administered to him or her,

(e) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘COVID-19 Vaccine (Vero Cell) Inactivated’, also known as ‘CoronaVac’, has been administered, that person not less than 14 days after the second dose of the medicinal product concerned has been administered to him or her,

(f) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘Inactivated COVID-19 (VERO CELL) vaccine’, also known as ‘SinoPharm / BIBP’ has been administered, that person not less than 14 days after the second dose of the medicinal product concerned has been administered to him or her, or

(g) in relation to a person to whom any combination of the medicinal products referred to in paragraphs (a), (b), (c), (e) and (f) has been administered -

(i) in the case of the second dose being the medicinal product referred to in
paragraph (a), that person not less than 14 days after the second dose of the medicinal product concerned has been administered to him or her,

(ii) in the case of the second dose being the medicinal product referred to in paragraph (b), that person not less than 15 days after the second dose of the medicinal product concerned has been administered to him or her,

(iii) in the case of the second dose being the medicinal product referred to in paragraph (c), that person not less than 7 days after the second dose of the medicinal product concerned has been administered to him or her,

(iv) in the case of the second dose being the medicinal product referred to in paragraph (e), that person, not less than 14 days after the second dose of the medicinal product concerned has been administered to him or her, or

(v) in the case of the second dose being the medicinal product referred to in paragraph (f), that person not less than 14 days after the second dose of the medicinal product concerned has been administered to him or her.

GIVEN under my Official Seal,
9 November, 2021.

STEPHEN DONNELLY,
Minister for Health.
EXPLANATORY NOTE

(This note is not part of the Instrument and does not purport to be a legal interpretation.)

Health Act 1947 (Sections 31AB and 31AD) (Covid-19) (Operation of certain indoor premises) (Amendment) (No. 8) Regulations 2021

These regulations extend the operation of S.I 385 of 2021 (Operation of certain indoor premises) to provide for the acceptance of heterologous vaccination courses and to extend the list of accepted vaccines to include vaccines from the WHO Emergency Use Listing (CoronaVac’ and ‘SinoPharm BIBP’). They extend the date of operation to 9th January.